Orthofix goes for experience with new chair Matricaria
This article was originally published in Clinica
Troubled Orthofix International will be hoping medical device veteran Ronald Matricaria, who it has just appointed director and chair, will be able to help dig it out of its current hole. The company is fighting delisting from the Nasdaq after delaying reporting its quarterly results, and also had a torrid 2013, with weak sales and questions over its business practices. In March 2013, it appointed Brad Mason CEO after previous incumbent Bob Vaters stepped down suddenly. New chair Mr Matricaria has over 35 years of experience at St Jude Medical and pharma giant Eli Lilly. He is also currently chair of Volcano and, most recently, served as a director at Life Technologies (acquired by Thermo Fisher for $13.6bn). He replaces Kathleen Regan, who has served as interim chair since January.